Actividades
Revisi�n art�culos (video) 6 de octubre de 2005
Movement Disorders Vol. 19, No. 7, 2004, pp. 812�828
Movement Disorders Vol. 19, No. 10, 2004, pp. 1139�1145
Movement Disorders Vol. 19, No. 8, 2004, pp. 907�915
Revisi�n art�culos (video) 13 de octubre de 2005
Movement Disorders Vol. 19, No. 8, 2004, pp. 962�988
Movement Disorders, Vol. 19, No. 7, 2004, pp 838
Movement Disorders, Vol. 19, No. 7, 2004, pp 842
17 de octubre de 2005
Cirug�a parkinson en CAS
Seminarios 24 de octubre de 2005
Fisiopatolog�a de los ganglios de la base
(1) Alexander GE, Crutcher MD. Functional architecture of basal ganglia circuits:
neural substrates of parallel processing. Trends Neurosci 1990; 13(7):266-271.
(2) Marsden CD, Obeso JA. The functions of the basal ganglia and the paradox of
stereotaxic surgery in Parkinson's disease. Brain 1994; 117 ( Pt 4):877-897.
(3) Obeso JA, Rodriguez-Oroz MC, Rodriguez M et al. Pathophysiology of the basal
ganglia in Parkinson's disease. Trends Neurosci 2000; 23(10 Suppl):S8-19.
Farmacoterapia de los ganglios de la base
(1) Calon F, Hadj TA, Blanchet PJ et al. Dopamine-receptor stimulation:
biobehavioral and biochemical consequences. Trends Neurosci 2000; 23(10 Suppl):S92-100.
(2) Chase TN, Oh JD. Striatal dopamine- and glutamate-mediated dysregulation in
experimental parkinsonism. Trends Neurosci 2000; 23(10 Suppl):S86-S91.
(3) Chase TN. Striatal plasticity and extrapyramidal motor dysfunction.
Parkinsonism Relat Disord 2004; 10(5):305-313.
Revisi�n art�culos (video) 27 de octubre de 2005
Movement Disorders, Vol. 19, No. 7, 2004 pp 836
Movement Disorders, Vol. 19, No. 7, 2004 pp 982
Movement Disorders, Vol. 19, No. 7, 2004 pp 1190
Revisi�n art�culos (video) 3 de noviembre de 2005
Movement Disorders, Vol. 19, No. 7, 2004 pp 833
Movement Disorders Vol. 19, No. 8, 2004, pp. 950�961
Movement Disorders, Vol. 19, No. 7, 2004 pp 1109
Seminario 7 de noviembre de 2005
Enfermedad de Parkinson, Etiolog�a, epidemiolog�a, tratamiento inicial.
(1) Jankovic J, Tolosa E. Parkinsons Disease and Movement Disorders. Third ed.
Baltimor: Williams & Wilkins, 1998.
(2) Koller WC. Treatment of early Parkinson's disease. Neurology 2002; 58(4
Suppl 1):S79-S86.
(3) Olanow CW. The role of dopamine agonists in the treatment of early
Parkinson's disease. Neurology 2002; 58(4 Suppl 1):S33-S41.
(4) Jenner P. Pharmacology of dopamine agonists in the treatment of Parkinson's
disease. Neurology 2002; 58(4 Suppl 1):S1-S8.
(5) Miyasaki JM, Martin W, Suchowersky O, Weiner WJ, Lang AE. Practice parameter:
initiation of treatment for Parkinson's disease: an evidence-based review:
report of the Quality Standards Subcommittee of the American Academy of
Neurology. Neurology 2002; 58(1):11-17.
(6) Olanow CW, Watts RL, Koller WC. An algorithm (decision tree) for the
management of Parkinson's disease (2001): treatment guidelines. Neurology 2001;
56(11 Suppl 5):S1-S88.
(7) Koller WC. Levodopa in the treatment of Parkinson's disease. Neurology 2000;
55(11 Suppl 4):S2-S7.
Revisi�n art�culos (video) 10 de noviembre de 2005
Movement Disorders, Vol. 19, No. 7, 2004 pp 1111
Movement Disorders Vol. 19, No. 8, 2004, pp. 965
Movement Disorders, Vol. 19, No. 7, 2004 pp.1317
Seminario 14 de noviembre de 2005
Enfermedad de Parkinson tratamiento avanzado, farmacocin�tica de la levodopa
y manejo de las complicaciones, motoras y no motoras.
(1) Jankovic J, Tolosa E. Parkinsons Disease and Movement Disorders. Third ed.
Baltimor: Williams & Wilkins, 1998.
(2) Factor SA. Literature review: intermittent subcutaneous apomorphine therapy
in Parkinson's disease. Neurology 2004; 62(6 Suppl 4):S12-S17.
(3) LeWitt PA. Subcutaneously administered apomorphine: pharmacokinetics and
metabolism. Neurology 2004; 62(6 Suppl 4):S8-11.
(4) Dewey RB, Jr. Management of motor complications in Parkinson's disease.
Neurology 2004; 62(6 Suppl 4):S3-S7.
(5) Poewe W. The role of COMT inhibition in the treatment of Parkinson's disease.
Neurology 2004; 62(1 Suppl 1):S31-S38
(6) Olanow CW, Watts RL, Koller WC. An algorithm (decision tree) for the
management of Parkinson's disease (2001): treatment guidelines. Neurology 2001;
56(11 Suppl 5):S1-S88.
(7) Wolters EC. Dopaminomimetic psychosis in Parkinson's disease patients:
diagnosis and treatment. Neurology 1999; 52(7 Suppl 3):S10-S13.
(8) Quinn NP. Classification of fluctuations in patients with Parkinson's
disease. Neurology 1998; 51(2 Suppl 2):S25-S29.
(9) Lieberman A. Managing the neuropsychiatric symptoms of Parkinson's disease.
Neurology 1998; 50(6 Suppl 6):S33-S38.
Seminario 21 de noviembre de 2005
Atrofia Multisistemica
(1) Wenning GK, Tison F, Seppi K et al. Development and validation of the
Unified Multiple System Atrophy Rating Scale (UMSARS). Mov Disord 2004;
19(12):1391-1402.
(2) Wenning GK, Geser F, Stampfer-Kountchev M, Tison F. Multiple system atrophy:
an update. Mov Disord 2003; 18 Suppl 6:S34-S42.
(3) Burk K, Skalej M, Dichgans J. Pontine MRI hyperintensities ("the cross sign")
are not pathognomonic for multiple system atrophy (MSA). Mov Disord 2001;
16(3):535.
(4) Silber MH, Levine S. Stridor and death in multiple system atrophy. Mov
Disord 2000; 15(4):699-704.
Revisi�n art�culos (video) 24 de noviembre de 2005
Movement Disorders, Vol. 19, No. 7, 2004 pp 1251
Movement Disorders Vol. 19, No. 8, 2004, pp. 1325
Movement Disorders, Vol. 19, No. 7, 2004 pp. 1334
Seminario 5 de diciembre de 2005
Paralisis Supranuclear Progresiva
(1) Osaki Y, Ben-Shlomo Y, Lees AJ et al. Accuracy of clinical diagnosis of
progressive supranuclear palsy. Mov Disord 2004; 19(2):181-189.
(2) Josephs KA, Dickson DW. Diagnostic accuracy of progressive supranuclear
palsy in the Society for Progressive Supranuclear Palsy brain bank. Mov Disord
2003; 18(9):1018-1026.
(3) Birdi S, Rajput AH, Fenton M et al. Progressive supranuclear palsy diagnosis
and confounding features: report on 16 autopsied cases. Mov Disord 2002;
17(6):1255-1264.
Seminario 12 de diciembre de 2005
Degeneracion corticobasal y demencia de Cuerpos de Lewy
(1) Graham NL, Bak TH, Hodges JR. Corticobasal degeneration as a cognitive
disorder. Mov Disord 2003; 18(11):1224-1232.
(2) Kertesz A. Pick's complex and FTDP-17. Mov Disord 2003; 18 Suppl 6:S57-S62.
(3) Lang AE. Corticobasal degeneration: selected developments. Mov Disord 2003;
18 Suppl 6:S51-S56.
(4) Vanek Z, Jankovic J. Dystonia in corticobasal degeneration. Mov Disord 2001;
16(2):252-257.
(5) Carella F, Ciano C, Panzica F, Scaioli V. Myoclonus in corticobasal
degeneration. Mov Disord 1997; 12(4):598-603.
(6) McKeith IG, Galasko D, Kosaka K et al. Consensus guidelines for the clinical
and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the
consortium on DLB international workshop. Neurology 1996; 47(5):1113-1124.
Revisi�n art�culos (video) 15 de diciembre de 2005
Movement Disorders, Vol. 19, No. 7, 2004 pp 1357
Movement Disorders Vol. 19, No. 8, 2004, pp. 1456
Movement Disorders, Vol. 19, No. 7, 2004 pp. 1518
Seminario 19 de diciembre de 2005
Parkinsonimo Vascular y otros parkinsonismos
(1) Zijlmans JC, Daniel SE, Hughes AJ, Revesz T, Lees AJ. Clinicopathological
investigation of vascular parkinsonism, including clinical criteria for
diagnosis. Mov Disord 2004; 19(6):630-640.
(2) Ondo WG, Chan LL, Levy JK. Vascular parkinsonism: clinical correlates
predicting motor improvement after lumbar puncture. Mov Disord 2002;
17(1):91-97.
(3) FitzGerald PM, Jankovic J. Lower body parkinsonism: evidence for vascular
etiology. Mov Disord 1989; 4(3):249-260.
Segundo periodo (fecha por definir)
Distonias Generalizada
(1) Berardelli A, Rothwell JC, Hallett M, Thompson PD, Manfredi M, Marsden CD.
The pathophysiology of primary dystonia. Brain 1998; 121 ( Pt 7):1195-1212.
(2) Nemeth AH. The genetics of primary dystonias and related disorders. Brain
2002; 125(Pt 4):695-721.
(3) Tinazzi M, Rosso T, Fiaschi A. Role of the somatosensory system in primary
dystonia. Mov Disord 2003; 18(6):605-622.
(4) Tassin J, Durr A, Bonnet AM et al. Levodopa-responsive dystonia. GTP
cyclohydrolase I or parkin mutations? Brain 2000; 123 ( Pt 6):1112-1121
Distonias Focales
(1) Berardelli A, Curra A. Pathophysiology and treatment of cranial dystonia.
Mov Disord 2002; 17 Suppl 2:S70-S74.
(2) Dauer WT, Burke RE, Greene P, Fahn S. Current concepts on the clinical
features, aetiology and management of idiopathic cervical dystonia. Brain 1998;
121 ( Pt 4):547-560.
Discinesias Paroxisticas y mioclonias
(1) Jankovic J, Tolosa E. Parkinsons Disease and Movement Disorders. Third ed.
Baltimor: Williams & Wilkins, 1998.
(2) Jarman PR, Davis MB, Hodgson SV, Marsden CD, Wood NW. Paroxysmal dystonic
choreoathetosis. Genetic linkage studies in a British family. Brain 1997; 120 (
Pt 12):2125-2130.
Temblor
(1) Deuschl G, Bain P, Brin M. Consensus statement of the Movement Disorder
Society on Tremor. Ad Hoc Scientific Committee. Mov Disord 1998; 13 Suppl
3:2-23.
(2) Vidailhet M, Jedynak CP, Pollak P, Agid Y. Pathology of symptomatic tremors.
Mov Disord 1998; 13 Suppl 3:49-54.
(3) Wasielewski PG, Burns JM, Koller WC. Pharmacologic treatment of tremor. Mov
Disord 1998; 13 Suppl 3:90-100.
TICS
(1) Robertson MM. Tourette syndrome, associated conditions and the complexities
of treatment. Brain 2000; 123 Pt 3:425-462.
(2) Jankovic J, Tolosa E. Parkinsons Disease and Movement Disorders. Third ed.
Baltimor: Williams & Wilkins, 1998.
Corea, Balismos y enfermedad de Huntington
(1) Jankovic J, Tolosa E. Parkinsons Disease and Movement Disorders. Third ed.
Baltimor: Williams & Wilkins, 1998.
Enfemedad de Wilson y Stiff Man
(1) Jankovic J, Tolosa E. Parkinsons Disease and Movement Disorders. Third ed.
Baltimor: Williams & Wilkins, 1998.
(2) Meinck HM, Thompson PD. Stiff man syndrome and related conditions. Mov
Disord 2002; 17(5):853-866.
(3) Gerschlager W, Brown P. Effect of treatment with intravenous immunoglobulin
on quality of life in patients with stiff-person syndrome. Mov Disord 2002;
17(3):590-593.